Skip to content

Cognitive training for mild cognitive impairment: a prospective clinical study

The effect of cognitive training for mild cognitive impairment patients

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-16008383
Enrollment
Unknown
Registered
2016-04-28
Start date
2016-05-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer Disease

Interventions

Sponsors

Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
55 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged 55-80 years old (including 55 and 80 years of age), no limitation of sex; 2. In accordance with the diagnostic criteria for "mild cognitive impairment due to alzheimer's disease" from National Institutes of Health National Institute on Aging-Alzheimer's Association (NIA - AA) (2011); 3. There are insufficiency in one or more cognitive domains. MMSE 24-28 points. Patients does not meet diagnostic criteria for dementia (DSM-IV-R); 4. The Hamilton depression rating scale / 17 edition (HAMD) total score70 years, white matter damage rating scale<=2; Lacunar infarcts larger than 2 cm in diameter<= 2; no infarcts in important parts such as the hypothalamus, entorhinal cortex, para-hupothalamus, cortical and subcortical cavity infarction near gray matter nuclei. The the MTA atrophy classification: grade II or above; 9. Neurological examination: no obvious signs; 10. Participants should have the caregiver stable and reliable. They contact frequently (at least 4 days a week, at least 2 hours per day), and caregivers will help patients to participate in the research process. Caregivers must accompany the participants in every visit, and must have good interaction with the subjects, in order to provide valuable information in ADCS - ADL, NPI rating scale; 11. Education: primary school (grade 6) or above. They have the ability to complete tests for cognitive ability, and have ability and time to complete regulation of cognitive training; 12. Before any examination or operation, subjects and their legal caregiver must sign written informed consent. If one cannot sign due to limited cognitive ability, we allow blank in subjects signing place. We need to explain the reason, and then ask for sign by the legal caregiver for the reasons. At the same time, the legal caregiver must sign a consent form.

Exclusion criteria

Exclusion criteria: 1. Other causes of cognitive decline: cerebrovascular disease, central nervous system infection, CJD, huntington's and Parkinson's disease, DLB, traumatic brain dementia, other physical and chemical factors (such as drugs, alcohol, CO), systemic disease (hepatic encephalopathy, pulmonary encephalopathy, etc.), intracranial occupation (a subdural hematoma, brain tumor), the endocrine system disease (thyroid disease, parathyroid disease), and vitamins deficiency or any other causes of dementia; 2. The history of nervous system diseases, including stroke, optic myelitis, Parkinson's disease, epilepsy, etc.); 3. Psychiatric patients, including schizophrenia or other mental illnesses, bipolar disorder, major depression or delirium; 4. There are abnormal laboratory indexes: liver function (ALT and AST) 1.5 times over upper level of standard range, creatine 1.5 times over upper level of standard range, moderate or severe anemia, fasting blood glucose value more than 1.5 over upper level of standard range; 5. Systolic blood pressure > 160 mmHg or 100 mmHg or < 60 mmHg; 6. There are unstable or serious heart, lung, liver, kidney, hematopoietic system disease; Poor prognosis because of malignant diseases such as tumor; 7. Vision or hearing problems that lead to poor performance of cognitive test; 8. Two years history of severe alcoholism, drug abuse; 9. Participated in other clinical trials within 30 days before the screening; 10. The researchers believe that the subjects could not complete the study.

Design outcomes

Primary

MeasureTime frame
AD incidence;

Secondary

MeasureTime frame
ADAS-Cog Score;ACE-R score;NPI;ADCS-ADL;

Countries

China

Contacts

Public ContactShengdi Chen

Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine

rj_neurology@126.com+86 021-64454473

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026